Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.
about
Clinical value of prostate segmentation and volume determination on MRI in benign prostatic hyperplasia.Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (ComDutasteride plus tamsulosin fixed-dose combination first-line therapy versus tamsulosin monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting.Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasiaManagement of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia by general practitioners in JakartaAssociation between self-perception period of lower urinary tract symptoms and International Prostate Symptom Score: a propensity score matching studyPatient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.itCinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase.Finasteride in the treatment of patients with benign prostatic hyperplasia: a reviewInvolvement of fibroblast growth factor receptor genes in benign prostate hyperplasia in a Korean population.Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey.Preliminary assessment of Neck Circumference in Benign Prostatic Hyperplasia in Patients with Metabolic SyndromeEmerging drugs for the treatment of benign prostatic obstruction.Current pharmacological treatment options for male lower urinary tract symptoms.The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP.Latest pharmacotherapy options for benign prostatic hyperplasia.Efficacy and Safety of Dutasteride in Chinese Adults with Symptomatic Benign Prostatic Hyperplasia : A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Extension.Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From MedicationAnalysis of initial baseline clinical parameters and treatment strategy associated with medication failure in the treatment of benign prostatic hyperplasia in KoreaAdherence to 5-alpha reductase inhibitor therapy for benign prostatic hyperplasia: clinical and economic outcomes.Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the manageCynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men.Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia.How much improvement is needed for a real difference of lower urinary tract symptoms after long-term combination therapy for benign prostatic hyperplasia.Sociodemographic and lifestyle factors affecting the self-perception period of lower urinary tract symptoms of international prostate symptom score items.Association between the self-perception period of lower urinary tract symptoms and the International Prostate Symptom Score.Therapeutic effect of α-blockers and antimuscarinics in male lower urinary tract symptoms based on the International Prostate Symptom Score subscore ratio.Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasiaPrescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia
P2860
Q30408224-341C9A54-B0D0-4271-83F0-E6811D8E49CAQ33602452-93A6F185-0B0F-486C-A1AD-685D1D0B1C53Q33829176-C55ED825-545A-4F63-A399-3AC53A44EDAAQ34539001-3EE95607-39D3-41CB-8D97-17EF52A4DFF8Q34630995-972715DE-5D25-480F-BB32-1B79F08D0B3FQ35207995-F28248E1-3A5A-47F6-9ABD-8AA74CDF0446Q35494498-20D0B7C0-62F1-4022-A60A-77EEED5518FFQ35782419-9512FC76-0E3B-462F-A392-86F023E147C4Q36379355-86AFD751-ED23-4A7F-8DE9-547D938CC32AQ37195621-3745FE10-77FC-4506-9D73-758A3AC4D73CQ37261063-408ECEB5-2BF4-4B1A-9C25-5FF381119AD0Q37411445-A5861475-5B39-41DB-AFDA-0AB543DD586FQ37456507-ADE7C251-84B7-4025-8938-A3106AE96C11Q37626508-237398B7-DB53-4FC6-9FDB-88CA9B6BC7C5Q37743490-71B42CBD-7FDC-48AA-AE3F-7675AC47DFC7Q38103891-919A753D-881F-4355-BABB-BBF471130294Q38136528-9155987F-BF72-404C-9379-E2B187591F3FQ38244053-5A3E3389-1220-4E88-B294-208D337E0D53Q39116956-B29669A6-14FF-4260-A21B-5BCF7A135140Q39284036-DA8A7222-36DE-4714-BEEF-0E7FCFCAD089Q39990115-9EF989FB-895F-4DDB-BC17-E644E2DDB364Q40636667-CFDB256D-5E88-41DD-A672-560E1F4F9A7CQ41875055-EAE907BA-29DF-42AC-A898-84DCE7496BE9Q42078804-071EB393-5B5B-497C-8DD6-7CF98BF79E2BQ43902268-9E76AD24-FF81-496D-ACEC-D249F41B37C0Q45339114-7DA4BCA1-336D-41CC-A98C-7941DD6F0AD8Q45785775-C19BA65F-2087-4CFA-92F5-AA15E1597733Q47614558-D1709C6D-AB42-461A-9A18-576E478022EAQ48081848-D985BEEF-CEF8-440E-9AC5-05BEB133484DQ53120555-BBA60E28-6AF3-47BE-9693-F53B040422C4Q53133756-0D27BCE3-2289-41DC-A511-654A514E4C40Q53137219-D4960D88-2C52-4D34-8205-8334A90F2233Q58283335-AEFB608A-6CCD-4B9F-87CC-082DB89A637FQ58763337-7A821E1F-15A6-4D6D-8825-3D1FBD525124
P2860
Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Benign prostatic hyperplasia a ...... ptions for medical management.
@ast
Benign prostatic hyperplasia a ...... ptions for medical management.
@en
type
label
Benign prostatic hyperplasia a ...... ptions for medical management.
@ast
Benign prostatic hyperplasia a ...... ptions for medical management.
@en
prefLabel
Benign prostatic hyperplasia a ...... ptions for medical management.
@ast
Benign prostatic hyperplasia a ...... ptions for medical management.
@en
P2093
P2860
P1476
Benign prostatic hyperplasia a ...... ptions for medical management.
@en
P2093
E B Cornel
J M F Gómez
M Emberton
R O Fourcade
P2860
P304
P356
10.1111/J.1742-1241.2008.01785.X
P577
2008-05-08T00:00:00Z